Overview

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention

Status:
Terminated

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

Pospective, single center, double-blind, randomised pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective Percutaneous Coronary Intervention (PCI). Eligible patients will be randomized for 30 day treatment to either 1) evolocumab 420 mg ; or 2) placebo.

Phase:

Phase 4

Details

Lead Sponsor:

Inova Health Care Services

Treatments:

Evolocumab